標(biāo)題: Titlebook: Antitrust in Pharmaceutical Markets & Geographical Rules of Origin; Pierre Kobel,Pranvera K?llezi,Bruce Kilpatrick Book 2017 The Editor(s) [打印本頁] 作者: estradiol 時(shí)間: 2025-3-21 18:42
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin影響因子(影響力)
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin影響因子(影響力)學(xué)科排名
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin網(wǎng)絡(luò)公開度
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin被引頻次
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin被引頻次學(xué)科排名
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin年度引用
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin年度引用學(xué)科排名
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin讀者反饋
書目名稱Antitrust in Pharmaceutical Markets & Geographical Rules of Origin讀者反饋學(xué)科排名
作者: folliculitis 時(shí)間: 2025-3-21 22:57
Austrial Act 2005 (hereafter referred to as “Cartel Act”) and the Austrian Competition Act 2002 (hereafter referred to as “Competition Act”). The Competition Act complements the Cartel Act and contains rules on the Federal Competition Authority (., hereafter referred to as FCA), its tasks, and some procedu作者: 嚴(yán)厲譴責(zé) 時(shí)間: 2025-3-22 02:51 作者: 新星 時(shí)間: 2025-3-22 06:30 作者: Conducive 時(shí)間: 2025-3-22 09:42
Hungaryrian Competition Authority. However, certain provisions of Hungarian pharmaceutical regulation are relevant from a competition law viewpoint (e.g. regulation promoting generic entry and prescribing a domestic supply obligation). The cases investigated by the Hungarian Competition Authority concern b作者: 增長 時(shí)間: 2025-3-22 13:16
Italyicle 2, on anticompetitive agreements, and Article 3, on abuse of dominant position, of Law 287/90 (the “Italian Antitrust Law” or the IAL), which contain the same principles of Articles 101 and 102 TFEU.作者: optic-nerve 時(shí)間: 2025-3-22 20:18 作者: Acquired 時(shí)間: 2025-3-22 22:18
Polandtion law. We consider the general legislative framework and specific provisions of pharmaceutical law concerning competition law aspects, as well as the enforcement of competition law in the pharmaceutical sector. We also reflect upon the interplay between competition law and intellectual property, 作者: 財(cái)主 時(shí)間: 2025-3-23 04:36
Swedenompetition rules or specific sectorial non-competition legislation. Swedish Competition Law enforcement has been, so far, sporadic at best, and has not addressed particularly “sexy” issues such as hardcore cases of refusal to license and pay-for-delay settlement agreements. Instead, the Swedish non-作者: periodontitis 時(shí)間: 2025-3-23 07:43 作者: Ingenuity 時(shí)間: 2025-3-23 11:39 作者: 領(lǐng)導(dǎo)權(quán) 時(shí)間: 2025-3-23 17:09
Ukraines no specific treatment of pharmaceutical products under the Ukrainian competition law. The law “On Protection of Economic Competition” (hereafter “Competition Law”) contains the main provisions regarding the protection of competition. In particular, the key provisions of Competition Law dealing wit作者: fetter 時(shí)間: 2025-3-23 19:50 作者: 珍奇 時(shí)間: 2025-3-24 00:17 作者: Myelin 時(shí)間: 2025-3-24 05:21
Wolfgang Kersten,Kirsten A. Schr?derral rules. New amendments of both Acts are currently in the pipeline, following European Directive 2014/104 on antitrust damages actions, which has to be implemented in the legal systems of all EU Member States by December 27, 2016.作者: languid 時(shí)間: 2025-3-24 08:03
E-Business in Produktionsnetzwerkention law and (iv) whether there is shared practice on budgetary and other public interest considerations. Particular attention is paid to market definition in de pharmaceutical sector, parallel trade and generic entry.作者: interpose 時(shí)間: 2025-3-24 11:36
Wissensmanagement im E-Commercevant competition law regulations, are directly applicable in the Czech Republic and therefore play a key role as regards the protection of competition in the Czech Republic. Nevertheless, this report focuses on national competition law.作者: Scintillations 時(shí)間: 2025-3-24 15:53
https://doi.org/10.1007/978-3-642-56831-2h infringements in the pharmaceutical sector relate to anticompetitive concerted actions (Article 6 of Competition Law), concerted actions on supply and use of goods (Article 8 of Competition Law), and abuse of dominance (Article 13 of Competition Law).作者: WITH 時(shí)間: 2025-3-24 22:11
Electronic Business und Multimediaf enforcement activity in this sector in the United States or, more recently, in the European Union. The Competition Commission has notably not had to struggle with reverse payment settlements and other issues at the crossroad of intellectual property and competition law.作者: Duodenitis 時(shí)間: 2025-3-25 00:40 作者: 招待 時(shí)間: 2025-3-25 05:09 作者: exceptional 時(shí)間: 2025-3-25 09:24 作者: endarterectomy 時(shí)間: 2025-3-25 12:47
Czech Republicvant competition law regulations, are directly applicable in the Czech Republic and therefore play a key role as regards the protection of competition in the Czech Republic. Nevertheless, this report focuses on national competition law.作者: Cumulus 時(shí)間: 2025-3-25 17:09 作者: VEN 時(shí)間: 2025-3-25 23:16 作者: doxazosin 時(shí)間: 2025-3-26 03:12
Electronic Business und Multimediahe enforcement of competition law in the pharmaceutical sector. We also reflect upon the interplay between competition law and intellectual property, and we include some budgetary considerations. At the end of our report, we briefly present our conclusions.作者: Detain 時(shí)間: 2025-3-26 05:38 作者: 孤僻 時(shí)間: 2025-3-26 12:27 作者: 虛構(gòu)的東西 時(shí)間: 2025-3-26 12:55 作者: 比賽用背帶 時(shí)間: 2025-3-26 20:05
https://doi.org/10.1007/978-3-322-82359-5n supplying wholesalers. The Hungarian consumer protection cases focus on false statements on the effect of products. In Hungary, there is only negligible private enforcement of competition law in the pharmaceutical sector, and neither public nor private enforcement is influenced by public funds involved.作者: muffler 時(shí)間: 2025-3-26 22:50 作者: 吹氣 時(shí)間: 2025-3-27 04:18 作者: consent 時(shí)間: 2025-3-27 08:43
Hungaryn supplying wholesalers. The Hungarian consumer protection cases focus on false statements on the effect of products. In Hungary, there is only negligible private enforcement of competition law in the pharmaceutical sector, and neither public nor private enforcement is influenced by public funds involved.作者: DALLY 時(shí)間: 2025-3-27 11:12 作者: 別名 時(shí)間: 2025-3-27 14:22 作者: 窒息 時(shí)間: 2025-3-27 18:01 作者: figment 時(shí)間: 2025-3-28 01:45
2199-742X phic origin of their goods or services?” This section presents an international report, which offers an unparalleled comparative analysis of this topic, bringing together common themes and contrasting the vario978-3-319-85755-8978-3-319-55813-4Series ISSN 2199-742X Series E-ISSN 2199-7438 作者: 共同時(shí)代 時(shí)間: 2025-3-28 02:14
Antitrust in Pharmaceutical Markets & Geographical Rules of Origin作者: 季雨 時(shí)間: 2025-3-28 06:50 作者: 索賠 時(shí)間: 2025-3-28 12:36
Electronic Business und Multimedia at the wholesale level of trade. On the other hand, state subsidies of medical drugs with the aim of protecting consumers have also resulted in promoting of competition between original drugs, parallel traded drugs and generics. In effect, it seems as this has also been an effective tool in order t作者: 手段 時(shí)間: 2025-3-28 16:46 作者: Bereavement 時(shí)間: 2025-3-28 19:25 作者: instructive 時(shí)間: 2025-3-29 02:20 作者: 強(qiáng)化 時(shí)間: 2025-3-29 04:40
International Report as appellations and designations of origin). In particular, it considers how the laws of those countries that have prepared National Reports regulate the use of indications of source for goods and services.作者: 冷漠 時(shí)間: 2025-3-29 08:48
Antitrust in Pharmaceutical Markets & Geographical Rules of Origin978-3-319-55813-4Series ISSN 2199-742X Series E-ISSN 2199-7438 作者: Preamble 時(shí)間: 2025-3-29 14:55 作者: SNEER 時(shí)間: 2025-3-29 17:42
Electronic Business und Multimediaicle 2, on anticompetitive agreements, and Article 3, on abuse of dominant position, of Law 287/90 (the “Italian Antitrust Law” or the IAL), which contain the same principles of Articles 101 and 102 TFEU.作者: Neutral-Spine 時(shí)間: 2025-3-29 22:36
https://doi.org/10.1007/978-3-319-91665-1 as appellations and designations of origin). In particular, it considers how the laws of those countries that have prepared National Reports regulate the use of indications of source for goods and services.作者: BRIDE 時(shí)間: 2025-3-30 02:05 作者: Morsel 時(shí)間: 2025-3-30 07:48 作者: Self-Help-Group 時(shí)間: 2025-3-30 08:27
E-Business in Produktionsnetzwerkents and markets. Sub-questions discussed include (i) whether pharmaceutical products receive differentiated legal treatment under Belgian competition law, (ii) whether any differentiated enforcement mechanisms exist, (iii) the interaction of pharmaceutical intellectual property protection and competi作者: paradigm 時(shí)間: 2025-3-30 16:26
Wissensmanagement im E-Commerceotection of Competition and on Amendment to Certain Acts (Act on the Protection of Competition) as amended (the ‘.’). It is important to note that relevant competition law legislation on the European level, principally Articles 101 and 102 TFEU and Regulations 1/2003 and 139/2004 and also other rele作者: Neutral-Spine 時(shí)間: 2025-3-30 19:29 作者: 啤酒 時(shí)間: 2025-3-30 23:13 作者: 種植,培養(yǎng) 時(shí)間: 2025-3-31 03:27 作者: 殺死 時(shí)間: 2025-3-31 07:09 作者: excursion 時(shí)間: 2025-3-31 09:26
Electronic Business und Multimediaompetition rules or specific sectorial non-competition legislation. Swedish Competition Law enforcement has been, so far, sporadic at best, and has not addressed particularly “sexy” issues such as hardcore cases of refusal to license and pay-for-delay settlement agreements. Instead, the Swedish non-作者: 皺痕 時(shí)間: 2025-3-31 14:52 作者: Reservation 時(shí)間: 2025-3-31 20:48
Electronic Business und New Economy increasing amount of expensive, new pharmaceuticals entering the market and the strain that this puts on the Dutch healthcare budget. This increases the pressure on the affordability of healthcare in general, with the risk of disadvantaging patients with other needs. This chapter shows that the pha作者: 晚間 時(shí)間: 2025-3-31 22:35
https://doi.org/10.1007/978-3-642-56831-2s no specific treatment of pharmaceutical products under the Ukrainian competition law. The law “On Protection of Economic Competition” (hereafter “Competition Law”) contains the main provisions regarding the protection of competition. In particular, the key provisions of Competition Law dealing wit作者: ADOPT 時(shí)間: 2025-4-1 03:12
https://doi.org/10.1007/978-1-4615-3558-4 preventing, restricting or distorting competition and that are capable of having an effect on trade in the UK (see section 2). If the arrangement in question affects trade between Member States, Article 101 TFEU may apply. Section 9 provides for an exemption where the arrangement meets four criteri作者: Narcissist 時(shí)間: 2025-4-1 08:52 作者: 愛管閑事 時(shí)間: 2025-4-1 12:26
Frank Keuper (wissenschaftlicher Assistent)The federal legislation covering both competition law and consumer law issues arising, or potentially arising, in the pharmaceutical industry in Australia is the . (Cth) (the CCA). Competition law is primarily contained in Part IV.
